The Hospital Quality Alliance (HQA) program gives us the opportunity to systematically monitor the quality of hospital care nationwide. To gauge the importance of the HQA indicators, we examined the relationship between hospitals' performance on HQA quality indicators and mortality for Medicare enrollees admitted for acute myocardial infarction, congestive heart failure, and pneumonia. We found that higher condition-specific performance on this national quality reporting program is associated with lower risk-adjusted mortality for each of the three conditions. The relationship between high HQA performance and lower risk-adjusted mortality is an important validation for this national hospital quality rating program. [Health Affairs 26, no. 4 (2007):
T h e h o s p i t a l Quality Al liance (HQA) is the first national program to publicly report on detailed processbased quality of care provided by hospitals. 1 Based on provisions in the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003, the U.S. Department of Health and Human Services (HHS) instituted a program to collect data on key measures of hospitals' management of three common medical conditions-acute myocardial infarction (AMI), congestive heart failure (CHF), and pneumonia-and to withhold up to 0.4 percent of the Medicare fee schedule update for hospitals that choose not to participate. The HQA data provide hospitals with performance benchmarks and can be used to guide quality improvement. Moreover, these indicators give us a potentially important tool for monitoring the quality of care nationwide.
Although there exist other programs for rating hospitals, the HQA has quickly become the largest and most comprehensive program, with near-universal participation. The three conditions assessed in the HQA are common (they constitute more than 15 percent of Medicare hospital medical and surgical admissions) and have important impacts on patients' morbidity and mortality. Initial evaluation of the program has shown that hospitals vary greatly in quality performance. 2 The HQA performance indicators are derived from a broad consensus of experts and are usually based on strong evidence of efficacy. But how these quality metrics perform in the real world in identifying hospitals with better outcomes, such as lower risk-adjusted mortality across a number of clinical conditions, is largely unknown. Since the real goal of health care is to improve outcomes, it is of great interest to determine whether hospitals that perform well on the HQA measures also have better outcomes. The existence of such a relationship would bolster evidence of the validity of the HQA measures. In this study, we sought to determine whether higher performance on the HQA measures was associated with lower risk-adjusted mortality for the three important medical conditions.
Study Data And Methods
n Data. We used data from the 1 December 2005 release of the HQA program. These data report performance scores for 4,048 acute care hospitals for care provided from 1 April 2004 through 31 March 2005. Although HQA now has data on twenty process measures, we limited our analyses to the ten that are known as the "starter set" because MMA provides financial incentives for reporting only these ten measures. Therefore, while most hospitals report data on these ten measures, only a smaller number of hospitals also report data on the other ten. The recently passed Deficit Reduction Act (DRA) of 2005 increased the financial incentive to hospitals for reporting and allows the HHS secretary to expand the number of measures required for the incentives. (The HQA data can be accessed at http://www .hospitalcompare.hhs.gov.)
We linked the HQA data with data from the American Hospital Association (AHA) annual survey to obtain information about hospital characteristics. We also linked each of these data sets with the 2003 Medicare Provider and Analysis Review (MedPAR) Part A data set (100 percent file), which has discharge-level data for hospitalizations of all feefor-service (FFS) Medicare beneficiaries. The MedPAR data set provided patient demographic and clinical information through International Classification of Diseases, Ninth Revision (ICD-9), diagnoses for severity adjustment, as well as our primary outcome of mortality.
n Hospital quality metrics. For each hospital, we used ten HQA performance indicators to calculate a summary performance score for each of the three clinical conditions: AMI, CHF, and pneumonia. There were five performance indicators for AMI: aspirin at arrival, aspirin at discharge, beta-blocker at arrival, beta-blocker at discharge, and angiotensinconverting enzyme (ACE) inhibitor for left ventricular systolic (LVS) dysfunction; two indicators for CHF: left ventricular function assessment and ACE inhibitor for LVS dysfunction; and three indicators for pneumonia: initial antibiotic timing (antibiotics provided in four hours or less), pneumococcal vaccination, and oxygenation assessment.
For each hospital, we created conditionspecific summary scores if the hospital reported a sample size of at least twenty-five for all of the indicators for that condition. The summary score is the simple weighted average of all measures for that condition. For example, if a hospital's performance on the two CHF indicators was 90 percent (for indicator 1) and 96 percent (for indicator 2), the CHF summary score would be 93 percent. Because of the high level of correlation among the five AMI measures (Cronbach's alpha 0.85), we also calculated summary scores for hospitals that had adequate sample sizes (twenty-five or more) for four out of five AMI measures.
3 Finally, to ensure that our results were robust to different methods for calculating summary scores, we also calculated summary scores using alternative methods and found comparable results. 4 n Outcomes. Three subgroups of patients were chosen from the MedPAR database, and we limited our analyses to those age sixty-five or older. The first subgroup consisted of patients discharged with primary diagnosis of AMI (using ICD-9 codes 410.XX); the second included patients discharged with the primary diagnosis of CHF (ICD-9 codes 398.91 and 428.0-428.9); and the third subgroup consisted of patients discharged with the primary diagnosis of pneumonia (ICD-9 codes 480-486). We excluded patients who were admitted as a result of transfer from other inpatient acute care facilities or were transferred to another acute care facility. Inpatient mortality was used as our primary measure of clinical outcome. The MedPAR database also provided patients' age, race, sex, and comorbidities so that risk adjustment could be performed in our regression models using the Elixhauser comorbidity adjustment scheme. 5 This technique is now widely used and supported by the Agency for Healthcare Research and Quality (AHRQ) as the risk-adjustment method of choice; it accounts for both demographic information and the presence or absence of important comorbidities.
n Statistical analyses. We used analyses of variance and chi-square tests, as appropriate, to compare hospitals that reported data to the HQA with a sample size adequate for us to calculate a summary score for each condition and those that reported no data. We then built separate multivariable logistic regression models to determine if high performance on the condition-specific HQA metric was associated with lower condition-specific inpatient mortality. Separate models were built for AMI patients, CHF patients, and pneumonia patients, with each discharge as the unit of analysis and dead (versus alive) at discharge as the primary outcome. HQA scores were examined both as continuous variables and by quartiles of performance. In our first set of models, we created predicted probabilities of death in hospitals, stratified by that hospital's performance on HQA (by quartiles), for the person with average values for each of the covariates (age, race, sex, and each of the comorbidities in the Elixhauser scheme) in the entire data set. Next, we used generalized estimating equations to account for clustering of patients at the hospital level and again adjusted for patient characteristics including age, sex, race, and the absence or presence of each of thirty comorbidities. We then further adjusted for the characteristics of the hospital where the patient was treated, including bed size (in three categories), region (by four census categories), teaching status (member of the Council of Teaching Hospitals versus not), profit status (for-profit versus nonprofit), location (urban versus rural), and the presence or absence of a coronary or medical intensive care unit (ICU).
To gauge the potential clinical importance of our findings, we calculated the potential number of deaths avoided if patients in the hospitals with the lowest quartile of HQA quality performance had mortality rates of patients from hospitals with the highest quartile. We used our results on risk-adjusted mortality by quartile of HQA performance and the prevalence of admitted patients with the three conditions as evident in 2003 MedPAR data to perform the appropriate calculation. All analyses were conducted using SAS 9.1.
Study Results
Of the 4,648 hospitals listed in the AHA survey as hospitals that care for medical and surgical patients, 4,140 reported some data to the HQA program, and 3,720 of these reported adequate data to the HQA program to allow us to generate at least one summary score, although the number of hospitals for which we had summary scores varied by condition. Hospitals that choose not to report to the HQA are generally small and often critical-access hospitals. Characteristics of reporting hospitals and all U.S. hospitals (reporting and not) are described in Exhibit 1. Hospitals that reported adequate data to allow for the creation of summary scores varied in profit status, location (urban versus rural), and presence of ICUs.
n Association of HQA and risk-adjusted mortality. Hospitals in the bottom quartile of HQA performance had a predicted mortality of 10.8 percent for AMI, 5.0 percent mortality for CHF, and 7.9 percent mortality for pneumonia (Exhibit 2). Higher performance was consistently associated with lower adjusted mortality rates, as hospitals in the top quartile had nearly 1 percent lower mortality among patients with AMI, 0.4 percent among patients with CHF, and 0.8 percent among patients with pneumonia.
In our models that accounted for clustering, higher HQA performance was associated with lower mortality for each of the three conditions. For example, patients who were dis-charged from the top quartile of HQA performance in AMI had 11 percent lower odds of dying than patients who were discharged from hospitals in the bottom quartile of HQA AMI performance (odds ratio 0.89, 95 percent confidence interval 0.85, 0.94). Similarly, patients admitted to hospitals in the top quartile of CHF performance had 7 percent lower odds of death, and patients admitted to hospitals in the top quartile of pneumonia performance had 15 percent lower odds of death (Exhibit 3). These findings persisted and changed little when we controlled for hospital characteristics including teaching status, region, bed size, and urban versus rural location (Exhibit 3). n Clinical impact of differences in riskadjusted mortality. We calculated the potential number of deaths avoided if patients in the hospitals with the lowest quartile of HQA quality performance had the mortality rates of patients from hospitals with the highest quartile. For the three conditions, approximately 2,200 deaths would have been avoided (474 for AMI, 627 for CHF, and 1,112 for pneumonia).
Discussion
A major goal of the HQA program is to monitor hospital quality of care and drive quality improvement. The motivation for hospitals to improve their quality performance depends on the face validity of the indicators and the evidence that better performance on them is associated with better outcomes for patients. Thus, our findings-that higher performance on the AMI, CHF, and pneumonia HQA indicators was each associated with lower risk-adjusted mortality-provide important data that are likely to bolster the HQA's impact.
Although strong scientific evidence underpins many of the HQA performance measures, much of this evidence is based on efficacy studies and clinical trials. Thus, it was not obvious that hospitals with high performance on process indicators for a specific condition would have better outcomes for that condition in real-world operations, especially given the technical limitations of outcomes measurement and the differences between assessing ef- fectiveness and efficacy. Moreover, some of the measures are unlikely to have a direct impact on inpatient mortality. This is true for pneumococcal vaccinations for pneumonia patients and true in part for beta-blockers at the time of discharge, depending on whether betablockers were prescribed only at discharge or earlier. Thus, the strength and consistency of the associations we found, especially for AMI and pneumonia care, suggest that these measures identify hospitals with programs that ensure the provision of highquality care that likely extends beyond the specific processes measured in the HQA program. This level of effect of the HQA performance should help alleviate concerns that hospitals might focus only on the indicators being measured to the detriment of the patient's wellbeing. 6 n HQA progress and prospects. The HQA is an important development in the effort to provide publicly available data on hospital performance. The effort so far has focused primarily on three common medical conditions. Recently, the HQA program has added quality indicators, provided now by only a small number of hospitals, on surgical infection prevention. The DRA gave the Centers for Medicare and Medicaid Services (CMS) the option of expanding the set of "required" indicators even further, and the CMS has announced plans to require an expanded set of indicators going from the current number of ten to more than twenty. This effort to monitor quality of care nationally is likely to continue and be expanded to other areas of clinical care. We expect this system to play a central role in U.S. efforts to monitor and improve the quality of hospital care nationally.
n Comparison with a previous study. We are aware of only one previous examination of the relationship between HQA quality measures and risk-adjusted mortality at the hospital level. Rachel Werner and Ed Bradlow examined relationships between individual HQA measures and risk-adjusted mortality rates and had broadly similar findings. 7 They focused on differences between "high performers" (hospitals that performed at the seventyfifth percentile for all metrics) and "low performers" (hospitals that performed at the twenty-fifth percentile for all metrics) and found significant differences in mortality rates. We were able to examine the relationship between the HQA and outcomes across the entire spectrum of performance, and our findings suggest that the relationship is consistent: that across all four quartiles of HQA performance, mortality rates improve for each of the three conditions. Furthermore, we performed two sets of analyses: the first without adjusting for hospital characteristics and the second, with adjustment for hospital characteristics. By demonstrating that the results do not change meaningfully, our findings suggest a robust relationship between HQA measures and outcomes that is less likely to be attributable to unmeasured confounders.
n Clinical importance of our study. Although the differences in mortality rates across the four quartiles were statistically significant, one might wonder whether they were clinically meaningful or important. We believe that they are. First, the mortality benefit of being a patient in a hospital in the top (versus bottom) quartile is comparable to that of receiving a beta-blocker after an AMI versus not receiving one-roughly a 14 percent diminution in the rate of mortality. 8 Further, we calculated that if hospitals in the bottom quartile had mortality rates that were comparable to those in the top quartile, 2,200 fewer elderly Americans would die each year from the three conditions studied.
n Study limitations. The HQA program only examines process measures across three conditions, and although these conditions are common and a source of major morbidity and mortality, they make up only 15 percent of hos- "If hospitals in the bottom quartile had mortality rates that were comparable to those in the top quartile, 2,200 fewer elderly Americans would die each year." pital admissions. Also, we used administrative data to perform risk adjustment for in-hospital mortality; thus, our ability to fully account for differences in underlying risk among patients was limited.
Next, as described above, some of the metrics we used in calculating our summary scores have demonstrated long-term benefits but might be unlikely to improve mortality in the short term. Therefore, by including those metrics, we might have underestimated the strength of the relationship between HQA performance and mortality rates. Given that the HQA program does not differentiate between metrics that have short-versus longterm benefits and that previous investigators have generally included all of the HQA metrics that are part of the "starter set," we chose to not exclude any of the individual metrics.
Finally, despite the fact that our quality metrics focus on care for patients of all ages, our outcomes data were obtained from Medicare files and only assessed outcomes for the elderly. However, at least one previous study suggests that outcomes for the elderly closely track those for all patients in most hospitals. 9 I n this study we found that high performance on the HQA was associated with 7-15 percent lower odds of death for each of three clinical conditions. These data document the importance of the HQA indicators for patient outcomes and are likely to increase the impact of the CMS effort in quality reporting. With the recent passage of the DRA, it is clear that the United States has embarked on a continuing and expanding initiative to monitor the quality of hospital care. Our findings underscore the potential of this effort for improving quality of care and changing patient outcomes.
